Traumatic Brain Injury Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Traumatic Brain Injury market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Avid Radiopharmaceuticals,Hope Biosciences, Neurological Associates of West Los Angeles, SHINKEI Therapeutics, Inc, veriNOS operations GmbH, SanBio, Inc., Hope Biosciences, Novartis, veriNOS operations GmbH, Pharmos, NeuroVive Pharmaceutical AB, Remedy Pharmaceuticals, Inc., Neuren Pharmaceuticals Limited, BHR Pharma, LLC, Danish Headache Center, Novartis

[Nevada, United States] - DelveInsight's "Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Traumatic Brain Injury, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Traumatic Brain Injury Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Traumatic Brain Injury Market Report:
• The Traumatic Brain Injury market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: BHR Pharma, LLC announced that the SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery and it's a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury
• In October, 2024: POLYSAN Scientific & Technological Pharmaceutical Company announced that a study will access the efficacy and safety of treatment with CITOFLAVIN® in patients with non-penetrating moderately severe traumatic brain injury (TBI). The study recruits patients 18-60 years with TBI, corresponding to the clinical diagnosis of brain contusion, with GCS score 9 -14 at the time of inclusion , with the estimated time of initiation of therapy within 24 hours from the estimated or established time of trauma, with post-traumatic amnesia, confusion or disorientation and absence of indications for neurosurgery or other surgical intervention under general anesthesia.
• In October, 2024: Merz Pharmaceuticals GmbH announced that the purpose of their study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
• In October, 2024: Ipsen announced that their study will assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• The estimates show the incident population of Traumatic Brain Injury (TBI) in Japan to be 325 thousand cases in 2023, which is estimated to decrease by 2034.
• 66% of males and 34% of females in the 7MM suffered with Traumatic Brain Injury (TBI) in 2023. These cases are anticipated to rise in the forecast period (2024-2034).
• According to DelveInsight's analysis, the total incident cases of Traumatic Brain Injury (TBI) in 7MM were found to be 4,254 thousand in 2023 and are estimated to rise with a significant CAGR throughout the forecast period (2024-2034).
• Key Traumatic Brain Injury Companies are as follows: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Avid Radiopharmaceuticals,Hope Biosciences, Neurological Associates of West Los Angeles, SHINKEI Therapeutics, Inc, veriNOS operations GmbH, SanBio, Inc., Hope Biosciences, Novartis, veriNOS operations GmbH, Pharmos, NeuroVive Pharmaceutical AB, Remedy Pharmaceuticals, Inc., Neuren Pharmaceuticals Limited, BHR Pharma, LLC, Danish Headache Center, Novartis
• Key Traumatic Brain Injury Therapies are as follow: Ronopterin (VAS203), CEVA101, florbetapir F 18, Autologous HB-adMSCs,NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, HB-adMSCs, Rivastigmine, VAS203, Dexanabinol, NeuroSTAT, Glyburide, NNZ-2566, Progesterone, AMG 334, Rivastigmine
• Launching multiple stage Traumatic Brain Injury pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Traumatic Brain Injury market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Traumatic Brain Injury Overview:
Traumatic Brain Injury (TBI) is sudden damage to the brain caused by a blow or jolt to the head. Common causes include car or motorcycle crashes. falls, sports injuries, and assaults. Injuries can range from mild concussions to severe permanent brain damage.

Traumatic Brain Injury Epidemiology Segmentation:
The Traumatic Brain Injury market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Traumatic Brain Injury Severity-specific Incident Cases
• Traumatic Brain Injury Total Incident Cases
• Traumatic Brain Injury Gender-specific Cases
• Traumatic Brain Injury Age-specific Incident Cases

For more information about Traumatic Brain Injury companies working in the treatment market, visit https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Traumatic Brain Injury Market Insights
Traumatic brain injury is a complex condition caused by an external force or impact on the head, resulting in damage to the brain. Treatment typically involves medical intervention, rehabilitation, and support to manage symptoms and improve outcomes.

The treatment modalities vary extensively based on the severity of the injury and range from daily cognitive therapy sessions to radical surgery, such as bilateral decompressed craniotomies. Guidelines have been set forth regarding optimal TBI management, but they must be taken in the context of the situation and cannot be used in every individual circumstance.

Traumatic Brain Injury Drugs Uptake
• Antidepressant medications such as citalopram, methylphenidate, sertraline, and others are thought to work by affecting the levels of the brain's natural chemical messengers, called neurotransmitters, and adjusting the brain's response to them.
• Anticonvulsant medications such as sodium valproate, gabapentin, topiramate, and carbamazepine are used to suppress the rapid and excessive firing of neurons that start a seizure and can sometimes preventthe spread of a seizure within the brain and offer neuroprotection.
• Pain management medications such as acetaminophen, ibuprofen, and naproxen sodium are used to control pain stemming from TBI and the symptoms and effects related to the injury. Motor system medications, including baclofen, tizanidine, or cyclobenzaprine, act on the motor system to affect the chemical balance in the brain to control bodily movement.
• Ronopterin (VAS203) is an allosteric iNOS inhibitor and rapidly lowers excessive production of NO resulting from acute iNOS activation. It does not materially affect the physiological production of NO by other constitutive enzymes, which are essential for brain function.
• ABX-101 is a CaM inhibitor in Phase II of clinical development for the treatment of moderate and severe TBI. It is considered to be a viable option in TBI patients, improving recovery post-CNS injuries.
• SB623 is a proprietary, human (allogeneic) bone marrow-derived mesenchymal stem cell that is produced by modifying and culturing mesenchymal stem cells derived from the bone marrow aspirate of healthy adults.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Traumatic Brain Injury Therapies and Key Companies:
• Ronopterin (VAS203): VeriNOS Pharmaceuticals GmbH
• CEVA101: Cellvation, Inc.
• florbetapir F 18: Avid Radiopharmaceuticals
• Autologous HB-adMSCs: Hope Biosciences
• NE3107:
• Neurological Associates of West Los Angeles
• Amantadine Hydrochloride: SHINKEI Therapeutics, Inc
• VAS203: veriNOS operations GmbH
• SB623 cells: SanBio, Inc.
• HB-adMSCs: Hope Biosciences
• Rivastigmine: Novartis
• VAS203: veriNOS operations GmbH
• Dexanabinol: Pharmos
• NeuroSTAT: NeuroVive Pharmaceutical AB
• Glyburide: Remedy Pharmaceuticals, Inc.
• NNZ-2566: Neuren Pharmaceuticals Limited
• Progesterone: BHR Pharma, LLC
• AMG 334: Danish Headache Center
• Rivastigmine: Novartis

Traumatic Brain Injury Epidemiology:
As the market is derived using the patient-based model, the Traumatic Brain Injury epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of TBI, Severity-specific Incident Cases of TBI, Gender-specific Incident Cases of TBI, and Age-specific Incident Cases of TBI in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

• According to DelveInsight estimations, 4,197 thousand Incident Cases of Traumatic Brain Injury were found in 2022 in the 7MM
• As per DelveInsight's estimations, the total number of cases with Traumatic Brain Injury in the United States were 2,964 thousand in 2022 and are projected to increase during the forecast period.
• According to DelveInsight's estimates, the Total Incident Cases of Traumatic Brain Injury in EU4 and the UK were found to be 906 thousand in 2022. The highest proportion of Traumatic Brain Injury cases was reported in Germany among the EU4 countries, while the least number of cases was found in Spain.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Traumatic Brain Injury Market Drivers:
• TBI is a significant global health issue, with a growing number of cases due to a rising number of head injuries and increasing awareness.
• Advances in medical technology have led to better diagnosis, treatment, and management options for TBI, including neuroimaging techniques and neuroprotective drugs.

Traumatic Brain Injury Market Barriers:
• There is no approved therapy for the treatment of TBI.
• Treatment protocols for TBI can vary widely, leading to inconsistencies in patient outcomes and challenges in establishing standardized care practices.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Traumatic Brain Injury Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Avid Radiopharmaceuticals,Hope Biosciences, Neurological Associates of West Los Angeles, SHINKEI Therapeutics, Inc, veriNOS operations GmbH, SanBio, Inc., Hope Biosciences, Novartis, veriNOS operations GmbH, Pharmos, NeuroVive Pharmaceutical AB, Remedy Pharmaceuticals, Inc., Neuren Pharmaceuticals Limited, BHR Pharma, LLC, Danish Headache Center, Novartis
• Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, florbetapir F 18, Autologous HB-adMSCs,NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, HB-adMSCs, Rivastigmine, VAS203, Dexanabinol, NeuroSTAT, Glyburide, NNZ-2566, Progesterone, AMG 334, Rivastigmine
• Traumatic Brain Injury Therapeutic Assessment: Current marketed and emerging therapies
• Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury Market drivers and Traumatic Brain Injury barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Traumatic Brain Injury Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Traumatic Brain Injury market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/traumatic-brain-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Traumatic Brain Injury (TBI) Market Overview by Therapy
4. Epidemiology and Market Methodology of TBI
5. Executive Summary of TBI
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Therapies
11. Traumatic Brain Injury: The Seven Major Market Analysis
12. Key Opinion Leaders' Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.